Quoin Pharmaceuticals Ltd DRC
$ 13.99
0.65%
26 Dec - close price
- Market Cap 11,737,300 USD
- Current Price $ 13.99
- High / Low $ 14.05 / 13.10
- Stock P/E N/A
- Book Value -2.06
- EPS -29.17
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.99 %
- ROE -6.51 %
- 52 Week High 28.35
- 52 Week Low 5.01
About
None
Analyst Target Price
$40.67
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-11 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-13 | 2023-11-08 | 2023-08-02 | 2023-05-08 | 2023-03-08 |
| Reported EPS | -6.72 | -6.3 | -6.502 | -0.2781 | -0.47 | -0.39 | -1.11 | -2.08 | -1.95 | -2.13 | -0.34 | -0.41 |
| Estimated EPS | -0.6 | -0.56 | -4.2 | -0.43 | -0.49 | -0.61 | -0.76 | -2.31 | -2.72 | -2.82 | -0.28 | -0.62 |
| Surprise | -6.12 | -5.74 | -2.302 | 0.1519 | 0.02 | 0.22 | -0.35 | 0.23 | 0.77 | 0.69 | -0.06 | 0.21 |
| Surprise Percentage | -1020% | -1025% | -54.8095% | 35.3256% | 4.0816% | 36.0656% | -46.0526% | 9.9567% | 28.3088% | 24.4681% | -21.4286% | 33.871% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QNRX
2025-11-25 10:09:59
Quoin Pharmaceuticals has successfully achieved target loading concentrations of 4% and 5% rapamycin for its proprietary topical lotion and dermal patch delivery technologies, respectively. The company plans to start manufacturing clinical trial and stability batches in Q4 2025 and commence clinical testing in the first half of 2026 for indications like Microcystic Lymphatic Malformations and Venous Malformations, where no FDA approved treatments currently exist. This milestone complements Quoin's existing pipeline, including late-stage programs for Netherton Syndrome and Peeling Skin Syndrome, and supports further clinical development.
2025-11-11 15:04:00
Quoin Pharmaceuticals Ltd.'s stock (NASDAQ: QNRX) is experiencing a significant uptrend, rising by 30.59% due to positive FDA designations and promising clinical trial results for QRX003 in Netherton Syndrome. The company has also strengthened its financial position, extending its cash runway into 2027, despite some lingering financial challenges. While market volatility is present, strategic advancements and regulatory backing suggest potential for sustained stock movement.
2025-11-11 08:30:00
Quoin Pharmaceuticals has successfully achieved target loading concentrations of 4% and 5% rapamycin for its proprietary topical lotion and dermal patch delivery technologies, respectively. The company plans to begin manufacturing clinical trial and stability batches in Q4 2025, with clinical testing for indications like Microcystic Lymphatic Malformations and Venous Malformations expected to start in H1 2026. This milestone is considered a significant step forward for Quoin's rapamycin programs and complements its existing pipeline.
2025-11-10 14:09:36
Quoin Pharmaceuticals (NASDAQ: QNRX) has successfully achieved target topical rapamycin loadings of 4% w/w in a proprietary lotion and 5% w/w in a dermal patch. The company plans to manufacture clinical trial and stability batches in Q4 2025 and begin clinical testing in multiple indications, including microcystic lymphatic malformations and venous malformations, in 1H 2026. This milestone is a significant step forward, as there are currently no FDA-approved treatments for these target indications.
2025-11-08 04:33:08
Quoin Pharmaceuticals (NASDAQ: QNRX) provided a corporate update and Q3 2025 results on November 6, 2025, detailing a private placement financing up to $105.3 million and a cash position of $5.4 million as of September 30, 2025, expected to fund operations into 2027. The company announced that QRX003 received FDA Orphan Drug designation for Netherton Syndrome, with pivotal enrollment for the drug scheduled to begin in Q4 2025, alongside an expanded pediatric program. Additionally, Sally Lawlor was appointed CFO, and the "NETHERTON NOW" awareness campaign reached over 1.5 million video views.
2025-11-08 04:33:08
Quoin Pharmaceuticals announced it will provide a corporate update and release its third-quarter 2025 financial results on Thursday, November 6, 2025. The company, which specializes in rare and orphan diseases, will highlight key achievements and financial performance for the quarter ending September 30, 2025, before the market opens.
